sugar disorders
DESCRIPTION
Sugar Disorders. SUGAR DISORDERS. DM (2008: 8 percent of the U.S. population has diabetes.). 15.8 million (2005) T1- 1 million T2-14.8 million ‘Other’ DM-TRANSCRIPT
![Page 1: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/1.jpg)
1
Sugar DisordersSugar Disorders
![Page 2: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/2.jpg)
2
SUGAR DISORDERSSUGAR DISORDERS
![Page 3: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/3.jpg)
3
DM (2008: 8 percent of the U.S. population has diabetes.)
15.8 million (2005)15.8 million (2005) T1- 1 millionT1- 1 million T2-14.8 millionT2-14.8 million ‘‘Other’ DM-<20,000Other’ DM-<20,000 2008: 24 million, an increase of more than 3 million in two 2008: 24 million, an increase of more than 3 million in two
years (2007)years (2007)
![Page 4: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/4.jpg)
4
T1 and T2 Features
T1: (10% of cases)T1: (10% of cases) immune mediated 90%immune mediated 90% DKA+++DKA+++ Children and under 20 Children and under 20
(15/100,000)(15/100,000) Absent insulinAbsent insulin Increased GlucagonIncreased Glucagon Insulin antibodiesInsulin antibodies FH+FH+ ?virus: rubella/ coxsackie/?virus: rubella/ coxsackie/ cow’s milkcow’s milk
T2: (90% of cases)T2: (90% of cases) DKA absentDKA absent Genetics- insulin resistance and Genetics- insulin resistance and
Beta cell loss (chr.2- in Hispanics)Beta cell loss (chr.2- in Hispanics) High insulin levelsHigh insulin levels Gut Obesity#1 causeGut Obesity#1 cause ? leptin and ? leptin and
adiponectinadiponectin
![Page 5: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/5.jpg)
5
Metabolic SyndromeSyndrome X (Insulin resistance Syndrome)
Increased TGL (triglycerides)Increased TGL (triglycerides) Decreased HDL (high density lipoproteins – the good kind)Decreased HDL (high density lipoproteins – the good kind) HTN (hypertension)HTN (hypertension) Increased LDL (low density lipoproteins – bad kind)Increased LDL (low density lipoproteins – bad kind) Increased Uric AcidIncreased Uric Acid Truncal obesity (aka central obesity)Truncal obesity (aka central obesity) Increased clotting tendency and pro-inflammatory stateIncreased clotting tendency and pro-inflammatory state
![Page 6: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/6.jpg)
6
Clinical Features of DM
T1T1 T2T2
Polyuria and thirstPolyuria and thirst ++++ ++
Weakness or FatigueWeakness or Fatigue ++++ ++
Polyphagia and Weight loss Polyphagia and Weight loss ++++ --
Recurrent blurred visionRecurrent blurred vision ++ ++++
Vulvovaginitis or pruritusVulvovaginitis or pruritus ++ ++++
Peripheral neuropathyPeripheral neuropathy ++ ++++
Nocturnal enuresisNocturnal enuresis ++++ --
Often asymptomaticOften asymptomatic -- ++++
![Page 7: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/7.jpg)
7
T2 diabetics
Waist to Hip ratio-Waist to Hip ratio-Men greater than 0.9Men greater than 0.9Women greater than 0.8Women greater than 0.8
Indicates increased risk of diabetes in obese peopleIndicates increased risk of diabetes in obese people
![Page 8: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/8.jpg)
8
Current Blood Sugar Numbers
NormalNormal ImpairedImpaired DiabetesDiabetesMellitusMellitus
Fasting plasma Fasting plasma glucoseglucose
Less thanLess than100 mg/dL100 mg/dL
100-125100-125mg/dLmg/dL
≥≥126 mg/dL*126 mg/dL*
Two hours after Two hours after glucose loadglucose load
≤ ≤ 140 mg/dL140 mg/dL ≥≥140-199 mg/dL140-199 mg/dL ≥ ≥ 200 mg/dL200 mg/dL
*126 or more on 2 occasions is diagnostic*126 or more on 2 occasions is diagnostic
![Page 9: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/9.jpg)
9
![Page 10: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/10.jpg)
10
![Page 11: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/11.jpg)
11
Glycated Hemoglobin A1c
Normal HgbA1c is 4-6%Normal HgbA1c is 4-6% Abnormally elevated in diabeticsAbnormally elevated in diabetics Reflects blood sugar levels over past 8-12 weeksReflects blood sugar levels over past 8-12 weeks If the value is greater than 2% then drug dose If the value is greater than 2% then drug dose
adjustments can be doneadjustments can be done
![Page 12: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/12.jpg)
12
Lipid abnormalities in DM
In T1 patients initial LDL is high but returns to normalIn T1 patients initial LDL is high but returns to normal In T2 patients- TGL is high/ low HDL/ altered LDL more In T2 patients- TGL is high/ low HDL/ altered LDL more
atherosclerosisatherosclerosis
![Page 13: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/13.jpg)
13
Non Diabetic causes for high blood sugar
Endocrinal- high steroids/ high GH/ glucagon tumorsEndocrinal- high steroids/ high GH/ glucagon tumors Drugs- niacin/ steroids/ diureticsDrugs- niacin/ steroids/ diuretics Liver diseaseLiver disease
![Page 14: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/14.jpg)
14
Diabetes Management
Clinical Trials Data:Clinical Trials Data: T1 patients:T1 patients: Tight glycemic controls reduce complications by 60% but Tight glycemic controls reduce complications by 60% but
increase the risk of therapy induced hypoglycemia three fold!increase the risk of therapy induced hypoglycemia three fold!
T2 patients: T2 patients: ‘impaired glucose/ “prediabetes” group- ‘impaired glucose/ “prediabetes” group- PREVENTION!: Low fat diet and 150 minutes of brisk walk/week PREVENTION!: Low fat diet and 150 minutes of brisk walk/week reduced progression to Dm by 71%. Preventive drug therapy reduced progression to Dm by 71%. Preventive drug therapy not usefulnot useful
![Page 15: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/15.jpg)
15
Kumamoto studyUKPDSstudy Steno-2 study
Data: Intensive treatment of T2 DM with drugs/ achieving Data: Intensive treatment of T2 DM with drugs/ achieving HgbA1c levels less than 7% with glypizide/ glyburide (HgbA1c levels less than 7% with glypizide/ glyburide (not not metformin or chlorpropamide)metformin or chlorpropamide) reduced diabetes related reduced diabetes related microvascular complications by 50%microvascular complications by 50%
![Page 16: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/16.jpg)
16
DM management
DietDiet DrugsDrugs InsulinInsulin Steps- Diagnosis/ Patient educationSteps- Diagnosis/ Patient education Acceptable levels of glycemic controlAcceptable levels of glycemic control Chronic Complications of DMChronic Complications of DM
![Page 17: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/17.jpg)
17
DIET
Determine calorie requirementsDetermine calorie requirements 45-65% from carbohydrate sources*45-65% from carbohydrate sources* 25-35% from fat (7% saturated)25-35% from fat (7% saturated) 10-35% from proteins10-35% from proteins
•*In T2 patients limit carbohydrates by *In T2 patients limit carbohydrates by substituting calories with mono-unsaturated substituting calories with mono-unsaturated fatty acids: olive oil/ rapeseed (canola)/ oils fatty acids: olive oil/ rapeseed (canola)/ oils in nuts or avocados. This will help to lower in nuts or avocados. This will help to lower TGL/ increase HDLTGL/ increase HDL
![Page 18: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/18.jpg)
18
Additional dietary caveats:
Limit cholesterol consumption to 200-300 mg/dayLimit cholesterol consumption to 200-300 mg/day Restrict protein intake to 10% of calorie requirements if there Restrict protein intake to 10% of calorie requirements if there
is renal failureis renal failure High soluble fiber dietHigh soluble fiber diet Artificial sweeteners only in limited usageArtificial sweeteners only in limited usage
![Page 19: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/19.jpg)
19
T2: Drugs for sugar control
1.1. Stimulate beta cells sulfonyl urea receptorsStimulate beta cells sulfonyl urea receptors2.2. Alter insulin actionAlter insulin action3.3. Affect dietary glucose absorptionAffect dietary glucose absorption4.4. Incretin mimetics or prolong incretin actionIncretin mimetics or prolong incretin action5.5. Glucagon suppressorsGlucagon suppressors
![Page 20: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/20.jpg)
20
# 1 -Stimulate beta cells # 1 -Stimulate beta cells
Second generation sulfonylureas-Second generation sulfonylureas-Glyburide (DiaGlyburide (Diaββeta)/ Glipizide (Glucotrol)eta)/ Glipizide (Glucotrol)
Glimeperide (Amaryl)Glimeperide (Amaryl) : Act for 12-24 hrs : Act for 12-24 hrs
Can cause prolonged hypoglycemiaCan cause prolonged hypoglycemia
Caution in hepatic impaired patientsCaution in hepatic impaired patients Repaglinide (Prandin)/ Nateglinide (Starlix):Repaglinide (Prandin)/ Nateglinide (Starlix):
stimulates insulin secretion, but less hypoglycemic stimulates insulin secretion, but less hypoglycemic
Induce weight gainInduce weight gain
![Page 21: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/21.jpg)
21
# 2 Drugs that alter insulin action
Biguanides- Biguanides- Metformin (Glucophage)Metformin (Glucophage) Reduces hepatic gluconeogenesisReduces hepatic gluconeogenesis Appetite suppressantAppetite suppressant GI upset- (20%) anorexia/nausea/vomiting/bloating/ GI upset- (20%) anorexia/nausea/vomiting/bloating/
diarrheadiarrhea Lactic acidosisLactic acidosis Does not cause hypoglycemiaDoes not cause hypoglycemia
![Page 22: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/22.jpg)
22
# 2 Drugs that alter insulin action
‘‘Glitazones’: Rosi (Avandia)/ Pio (Actos)Glitazones’: Rosi (Avandia)/ Pio (Actos) Alters the genetic expression of resistin (blocked) and adiponectin (stimulated) Alters the genetic expression of resistin (blocked) and adiponectin (stimulated)
from fat cells. from fat cells. Adiponectin normally increases insulinAdiponectin normally increases insulin sensitivitysensitivity of the tissues of the tissues Resistin normally causes insulin Resistin normally causes insulin resistanceresistance. Blocking it reduces insulin resistance. Blocking it reduces insulin resistance Decreases free fatty acids/ decreases hepatic glucose output. Does not cause Decreases free fatty acids/ decreases hepatic glucose output. Does not cause
hypoglycemiahypoglycemia BUT increase- total cholesterol/LDL/HDLBUT increase- total cholesterol/LDL/HDL AVANDIA increases risk of angina/MI AVANDIA increases risk of angina/MI not prescribed but ACTOS is ok.not prescribed but ACTOS is ok.
![Page 23: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/23.jpg)
23
# 3 Affect dietary glucose absorptionAffect dietary glucose absorption
Alpha glucosidase inhibitors- Alpha glucosidase inhibitors- Acarbose (Precose) / Miglitol (Glyset)Acarbose (Precose) / Miglitol (Glyset) Reduces postprandial hyperglycemiaReduces postprandial hyperglycemia Side effects – flatulence (30%)Side effects – flatulence (30%)
![Page 24: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/24.jpg)
24
Gila Monster Heloderma suspectum
![Page 25: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/25.jpg)
25
# 4 Incretins
Exenatide (Byetta)- GLP-1 receptor Exenatide (Byetta)- GLP-1 receptor agonist from the saliva of venomous agonist from the saliva of venomous lizard- Gila Monsterlizard- Gila Monster
Suppresses glucagon release and delays gastric emptyingSuppresses glucagon release and delays gastric emptying Helps to reduce HbA1c and lose weight – risks hypoglycemia and Helps to reduce HbA1c and lose weight – risks hypoglycemia and
pancreatitis, affects other drugs gastric emptyingpancreatitis, affects other drugs gastric emptying
Sitagliptin (Januvia) Sitagliptin (Januvia) (DPP-4= Di-Peptidyl-Peptidase-4 enzyme) inhibitor(DPP-4= Di-Peptidyl-Peptidase-4 enzyme) inhibitor
Improves HbA1c. No weight loss. Nasopharyngitis/URTIImproves HbA1c. No weight loss. Nasopharyngitis/URTI
![Page 26: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/26.jpg)
26
# 5 Other drugs
Pramlintide (Pramlintide (SymlinSymlin) analog of islet cell polypeptide amylin) analog of islet cell polypeptide amylin Delays gatric emptying, suppresses glucagon secretion and Delays gatric emptying, suppresses glucagon secretion and
decreases appetite. decreases appetite. Used in T1 and T2Used in T1 and T2
![Page 27: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/27.jpg)
27
# Insulin and T1/T2 Produced by rDNA technology ‘human’ insulinsProduced by rDNA technology ‘human’ insulins Action: Onset/Peak/DurationAction: Onset/Peak/Duration Rapidly acting-5’-15’/1-1.5hrs/3-4hrsRapidly acting-5’-15’/1-1.5hrs/3-4hrs Insulin lispro (Humalog), aspart (Novolog), glulisine (Apidra)Insulin lispro (Humalog), aspart (Novolog), glulisine (Apidra)
Short acting regular- 30-60’/2hrs/6-8hrsShort acting regular- 30-60’/2hrs/6-8hrs Intermediate acting- 2-4hrs/6-7hrs/10-20hrsIntermediate acting- 2-4hrs/6-7hrs/10-20hrs NPH insulinNPH insulin
‘‘Premixed’ NPH/Regular marketed as 70/30 or 50/50 or Premixed’ NPH/Regular marketed as 70/30 or 50/50 or 75/2575/25
Long-Acting glargine (Lantus)- 1.5hrs/falt/~24 hrsLong-Acting glargine (Lantus)- 1.5hrs/falt/~24 hrs detemir (Levemir)- 1 hr/ flat/17hrsdetemir (Levemir)- 1 hr/ flat/17hrs
![Page 28: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/28.jpg)
28
DM Issues
Watch out and recognize hypoglycemic features in patients Watch out and recognize hypoglycemic features in patients being treated with insulinbeing treated with insulin
Complications of DM that increase the risk of hypoglycemia- Complications of DM that increase the risk of hypoglycemia- autonomic neuropathy/ gastroparesis/ renal failureautonomic neuropathy/ gastroparesis/ renal failure
Lipodystrophy at injection siteLipodystrophy at injection site
![Page 29: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/29.jpg)
29
Chronic complications of DM
1.1. Ocular- Ocular- Cataracts/ Retinopathy/ GlaucomaCataracts/ Retinopathy/ Glaucoma
2.2. Renal- Renal- ESRD (T1>T2)/(good glycemic control and use of ACEi can reduce ESRD (T1>T2)/(good glycemic control and use of ACEi can reduce the development) Always check for proteinurithe development) Always check for proteinuri
3.3. Neuropathy-Neuropathy-Distal symmetrical ‘neuritis’- pain, touch, temp, vibration/ Distal symmetrical ‘neuritis’- pain, touch, temp, vibration/ claw toes-calluses and ulcers Charcot’s arhtropathy; burning pain claw toes-calluses and ulcers Charcot’s arhtropathy; burning pain (hypersensitivty)(hypersensitivty)Autonomic neuropathy/ EDAutonomic neuropathy/ ED
![Page 30: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/30.jpg)
30
Chronic complications of DM
44 Cardiovascular- Cardiovascular- heart failure-cardiomyopathy-IHD-metabolic heart failure-cardiomyopathy-IHD-metabolic syndrome-HTN-microvasculitis - peripheral vascular disease and syndrome-HTN-microvasculitis - peripheral vascular disease and gangrenegangrene
55 Skin and mucous membrane- Skin and mucous membrane- necrobiosis-candidiasisnecrobiosis-candidiasis
66 Pregnancy and DM- Pregnancy and DM- tight control with normal HbA1c critical to tight control with normal HbA1c critical to reduce spontaneous miscarriages-congenital malformations-reduce spontaneous miscarriages-congenital malformations-polyhydramnios-preterm labor-still birth-fetal macrosomia; risk of polyhydramnios-preterm labor-still birth-fetal macrosomia; risk of retinopathy/ preeclmapsiaretinopathy/ preeclmapsia
![Page 31: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/31.jpg)
31
HYPOGLCEMIA!
Fasting- insulinomas/ Addison’s/ myxedema/liver Fasting- insulinomas/ Addison’s/ myxedema/liver malfunction/malfunction/
Postprandial-Postprandial- Alcohol mediated- blocks conversion of glycogen to glucose in Alcohol mediated- blocks conversion of glycogen to glucose in
the liverthe liver Drug induced- Quinine/ Quinidine/ Quinolones (?)Drug induced- Quinine/ Quinidine/ Quinolones (?)
![Page 32: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/32.jpg)
32
Managing hypoglycemia
If blood glucose is 70 mg/dL or below: Eat or drink 15 g of carbohydrates# Recheck your blood glucose in 15
minutes. If the reading is not above 60 mg/dL.
Test again in 15 minutes If blood glucose is not > 70 mg/dL, repeat
treatment with another 15 g of carbohydrate, then call your health care provider
#The following contain 15 g of carbohydrate and are appropriate for the treatmentof hypoglycemia:
Glucose tablets (3, 5 g tablets) 4 oz of juice or soda (not diet) 1 tablespoon of table sugar or honey 1 small box of raisins Another useful formula that can help
patients emerge safely from hypoglycemia without spiking into a glycemic state:
(100 - blood glucose) X 0:2 = grams of carbohydrates
necessary for blood glucose correction Thus, if the blood glucose is 50 mg/dL, the
patient would consume 100–50 = 50; 50X 0.2 = 10 g of carbohydrates
![Page 33: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/33.jpg)
33
Useful Lab Tests in Diabetes Care
Biochemistry-Biochemistry- Urine Analysis- Urine Analysis- Protein/Sugar/KetonesProtein/Sugar/Ketones Look for microalbuminurea in patients Look for microalbuminurea in patients
with DM duration greater than 10 yrs. with DM duration greater than 10 yrs. Early sign of kidney involvementEarly sign of kidney involvement
FBS/PPBS/RBSFBS/PPBS/RBS HbA1c (~6% or less)HbA1c (~6% or less) Lipid profileLipid profile BUN & CreatinineBUN & Creatinine Red flags-Red flags- Sugars less than 50 Sugars less than 50 Sugars greater than 250 Sugars greater than 250
Others-Others- ECG/ Stress testECG/ Stress test Doppler vascular studiesDoppler vascular studies Ophthalmic studies for cataracts/ Ophthalmic studies for cataracts/
retinal issuesretinal issues FGIDs (functional gastro intestinal FGIDs (functional gastro intestinal
disorders)disorders)
![Page 34: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/34.jpg)
34
Diabetic Foot! Charcot!
![Page 35: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/35.jpg)
35
Diabetic Foot Care Visual inspection, palpation of the foot, vascular and neurologic
assessment, dermatologic assessment, motorexamination, and determination of range of motion of the foot and ankle.
Look for: 1. Healing injuries, bruising, or skin disturbances; bunions, hammertoes, a rocker
bottom foot, or Achilles contracture2. Vascular skin changes: stasis dermatitis, skin atrophy, hair loss, nail changes, or
clear areas of decreased perfusion; dryness, scaling, swelling, thickening of the tissues, and the temperature of the foot
3. Presence or absence of pedal pulses, and degree of sensory loss (neuropathy)4. Check the toe web spaces for evidence of tinea pedis, maceration,
fissures, or ulceration. Global erythema and swelling may represent Charcot changes or cellulitis
![Page 36: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/36.jpg)
36
Diabetic Foot Care
Neurologic status: (50% affected)Recent onset of pain, numbness, tingling, or other paresthesias?Subjective sensory tests, with comparison to the contralateral limb-Loss of the Achilles deep tendon reflex128-hz tuning fork
![Page 37: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/37.jpg)
37
Define neuropathy!
![Page 38: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/38.jpg)
38
Peripheral neuropathy- pain or loss of feeling in the toes, feet, legs, hands, and armspain or loss of feeling in the toes, feet, legs, hands, and arms
Proximal neuropathy (amyotrophy)- pain in the thighs, hips, or buttocks, leading to weakness in the legspain in the thighs, hips, or buttocks, leading to weakness in the legs
Focal neuropathy-dysfunction of one group or a group of nerves, resulting in muscle weakness dysfunction of one group or a group of nerves, resulting in muscle weakness or painor pain
Distal symmetrical polyneuropathy- ‘stocking-and-glove’ typemost common
Cranial neuropathy- acute-onset diplopia with ptosis and papillary sparing associated with an ipsilateral headache
![Page 39: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/39.jpg)
39
Risk factors for the development of diabetic Risk factors for the development of diabetic neuropathyneuropathy Modifiable Modifiable risk factors Obesity Hypertriglyeridemia Cigarette smoking Hypertension Elevated A1C Glycemic variability
NonmodifiableNonmodifiable risk factors Duration of diabetes Age Family history of neuropathic
disease
![Page 40: Sugar Disorders](https://reader036.vdocuments.net/reader036/viewer/2022062309/56813693550346895d9e1db8/html5/thumbnails/40.jpg)
40
Drugs used in treating neuropathy:
Antidepressants: Duloxetine/ Venlafaxine/ Tricyclics (TCAs) Anticonvulsants: Pregabalin/ Gabapentin/ Carbamazepine/
Lamotrigine/ Topiramate/ Opioids: Oxycodone CR/ Tramadol/ Topical agents: Capsaicin/ Lidocaine Patch Miscellaneous: Magnesium oxide